Literature DB >> 18461515

Prevalence, aetiology and associated co-morbidities of elevated aminotransferases in a german cohort of orthopaedic surgery patients.

S Lobstein1, T Kaiser, U Liebert, M Wojan, A Leichtle, J Mössner, J Wiegand, H L Tillmann.   

Abstract

INTRODUCTION: In a recent study on hepatitis C prevalence, we identified a high prevalence of elevated liver enzymes, well above 10 %, in orthopaedic surgery patients without evidence for viral hepatitis. We now report in another cohort, that the prevalence is indeed in that range, and that in these patients elevated liver enzymes are likely indicators for existing comorbidities.
METHODS: 1064 patients referred to the Department of Orthopaedic Surgery, University of Leipzig, between January 2001 and July 2005 were screened routinely for serological markers against hepatitis B and C. Out of these patients 960 individuals were tested additionally for liver enzymes. Patients with elevated aminotransferases but no evidence for hepatitis B or C were compared with two age- and sex-matched controls with normal liver enzymes to evaluate differences in the frequency of comorbidities.
RESULTS: The prevalence of hepatitis B and C was low (HBs-antigen positive: 0.41 %, anti-HCV positive: 0 %). Of the 960 patients with no evidence for viral hepatitis and available aminotransferase values 108 cases (11.3 %) showed elevated ALT, 67 individuals (7 %) elevated AST and 125 patients (13 %) showed elevation of either one or both aminotransferases. Patients with elevated liver enzymes had a significantly higher prevalence of hypertension (73.6 vs. 57.2 %; p = 0.002), chronic ischaemic heart disease (CIHD) (30.4 vs. 15.6 %; p = 0.001), hyperlipidaemia (30.4 vs. 14.8 %; p = 0.001) and hyperuricaemia (36 vs. 23.6 %; p = 0.014). Type 2 Diabetes mellitus tended to be more frequent in patients with elevated liver enzymes, too (p = 0.056). Individuals with elevated aminotransferases presented a mean BMI of 28.7 kg/m (2) in comparison to 27.5 kg/m (2) in the control group (p = 0.055). By excluding patients with regular daily alcohol consumption, the prevalence of abnormal liver enzymes was still remarkably high (9 %).
CONCLUSION: Our study proved a high prevalence of elevated aminotransferases in orthopaedic surgery patients, most frequently caused by NAFLD, and its association with a high rate of concomitant diseases. Thus, abnormal liver enzymes should lead to a focused screening for concomitant diseases such as diabetes, hypertension and coronary atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18461515     DOI: 10.1055/s-2008-1027157

Source DB:  PubMed          Journal:  Z Gastroenterol        ISSN: 0044-2771            Impact factor:   2.000


  5 in total

1.  Screening for impaired liver function as a risk factor for drug safety at hospital admission of surgical patients.

Authors:  Dorothea Strobach; Angelika Poppele; Hanna Mannell; Monika Andraschko; Susanne Schiek; Thilo Bertsche
Journal:  Int J Clin Pharm       Date:  2019-12-05

Review 2.  Evaluation of elevated liver values in primary care - a series of studies on the status quo of care in Germany with special reference to alcoholic liver disease.

Authors:  Julian Wangler; Michael Jansky
Journal:  BMC Prim Care       Date:  2022-05-03

3.  Liver function parameters in hip fracture patients: relations to age, adipokines, comorbidities and outcomes.

Authors:  Leon Fisher; Wichat Srikusalanukul; Alexander Fisher; Paul Smith
Journal:  Int J Med Sci       Date:  2015-01-01       Impact factor: 3.738

4.  Working relationship between primary and specialist care in analysing elevated liver values-a survey from the point of view of gastroenterologists.

Authors:  Julian Wangler; Stefan Claus; Michael Jansky
Journal:  Wien Med Wochenschr       Date:  2021-06-29

5.  [Evaluation of abnormal liver chemistries in primary care - A survey on the prerequisites, procedure and challenges faced by general practitioners].

Authors:  Julian Wangler; Michael Jansky
Journal:  Z Gastroenterol       Date:  2020-08-24       Impact factor: 1.769

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.